Natural Interleukin-2 plus Lymphokine-Activated Killer Cells in Patients with Advanced Malignancy
H. Link(Medizinische Hochschule Hannover), H. Poliwoda, H. Mohr(German Red Cross), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), B. Sens, Ulrich Pohl(Centre of Experimental Medicine of the Slovak Academy of Sciences), Jennifer Andres, Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Mathias Freund(Universitätsmedizin Rostock), H. Kirchner(Medizinische Hochschule Hannover), C. Schöber, Anja Hoffmann(Helmholtz-Zentrum Dresden-Rossendorf), Jens Atzpodien(St. Franziskus Hospital), T Volgmann(Medizinische Hochschule Hannover)
Cited by 0
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Autologous bone-marrow stem-cell transplantation for myocardial regeneration
|The Lancet|2003|1.4k
Reactive Oxygen Species
|Arteriosclerosis Thrombosis and Vascular Biology|2004|1k
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
|Alzheimer s & Dementia|2015|605